WO2008112238A1 - 2, 8-diméthyl-5- [2- (6-méthylpyridin-3-yl) -éthyl] -2,3,4, 5-tétrahydro- ih- pyrido [4, 3 -b] indole dihydrochlorure (dimebon) pour le traitement de la douleur chronique - Google Patents

2, 8-diméthyl-5- [2- (6-méthylpyridin-3-yl) -éthyl] -2,3,4, 5-tétrahydro- ih- pyrido [4, 3 -b] indole dihydrochlorure (dimebon) pour le traitement de la douleur chronique Download PDF

Info

Publication number
WO2008112238A1
WO2008112238A1 PCT/US2008/003246 US2008003246W WO2008112238A1 WO 2008112238 A1 WO2008112238 A1 WO 2008112238A1 US 2008003246 W US2008003246 W US 2008003246W WO 2008112238 A1 WO2008112238 A1 WO 2008112238A1
Authority
WO
WIPO (PCT)
Prior art keywords
pain
detcd
subject
resulting
chronic
Prior art date
Application number
PCT/US2008/003246
Other languages
English (en)
Inventor
Louis Herlands
Original Assignee
Grey Fox Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grey Fox Llc filed Critical Grey Fox Llc
Publication of WO2008112238A1 publication Critical patent/WO2008112238A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Abstract

L'invention porte sur des méthodes de traitement de la douleur chronique, en particulier des douleurs chroniques neuropathique, inflammatoire et dues au syndrome de la fibromyalgie, chez un sujet, par administration à ce dernier de l'agent antihistaminique Dimebon ™ (DETCD). L'invention porte également sur des méthodes de traitement de la douleur chronique chez un patient par administration d'une combinaison de DETCD et d'un ou plusieurs agents, tel qu'un antidépresseur, un anticonvulsif, un antiarrhythmique, un anesthésique, un antagoniste du NMDA, ou un narcotique.
PCT/US2008/003246 2007-03-12 2008-03-12 2, 8-diméthyl-5- [2- (6-méthylpyridin-3-yl) -éthyl] -2,3,4, 5-tétrahydro- ih- pyrido [4, 3 -b] indole dihydrochlorure (dimebon) pour le traitement de la douleur chronique WO2008112238A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90638107P 2007-03-12 2007-03-12
US60/906,381 2007-03-12

Publications (1)

Publication Number Publication Date
WO2008112238A1 true WO2008112238A1 (fr) 2008-09-18

Family

ID=39586948

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/003246 WO2008112238A1 (fr) 2007-03-12 2008-03-12 2, 8-diméthyl-5- [2- (6-méthylpyridin-3-yl) -éthyl] -2,3,4, 5-tétrahydro- ih- pyrido [4, 3 -b] indole dihydrochlorure (dimebon) pour le traitement de la douleur chronique

Country Status (1)

Country Link
WO (1) WO2008112238A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2363120A1 (fr) * 2010-02-15 2011-09-07 Sanovel Ilac Sanayi ve Ticaret A.S. Mélange contenant du diméboline et de la mémantine
EP2236159A3 (fr) * 2009-03-31 2011-12-07 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions de Dimeboline à libération modifiée.
EP2236160A3 (fr) * 2009-03-31 2011-12-14 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions de Dimeboline à libération modifiée

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0876818A2 (fr) * 1995-10-23 1998-11-11 Nikolai Serafimovich Zefirov Agent therapeutique contre les troubles neurodegeneratifs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0876818A2 (fr) * 1995-10-23 1998-11-11 Nikolai Serafimovich Zefirov Agent therapeutique contre les troubles neurodegeneratifs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BACHURIN S ET AL: "Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES JUN 2001,, vol. 939, 1 June 2001 (2001-06-01), pages 425 - 435, XP002478538 *
BROWN DEAN G ET AL: "N-methyl-D-aspartate receptor (NMDA) antagonists as potential pain therapeutics.", CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 6, no. 8, 2006, pages 749 - 770, XP009103060, ISSN: 1568-0266 *
CAMMARATA D ET AL: "Memantine: Novel Mechanism for Migraine and Headache Prophylaxis", HEADACHE:THE JOURNAL OF HEAD AND FACE PAIN &47TH ANNUAL SCIENTIFIC MEETING AMERICAN HEADACHE SOCIETY JUNE 23-25, 2005, PHILADELPHIA, vol. 45, no. 6, June 2005 (2005-06-01), pages 820 - S103, XP002487889, ISSN: 1365-2524 *
SONKUSARE S K ET AL: "Dementia of Alzheimer's disease and other neurodegenerative disorders-memantine, a new hope", PHARMACOLOGICAL RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 51, no. 1, 1 January 2005 (2005-01-01), pages 1 - 17, XP004616758, ISSN: 1043-6618 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2236159A3 (fr) * 2009-03-31 2011-12-07 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions de Dimeboline à libération modifiée.
EP2236160A3 (fr) * 2009-03-31 2011-12-14 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions de Dimeboline à libération modifiée
EP2363120A1 (fr) * 2010-02-15 2011-09-07 Sanovel Ilac Sanayi ve Ticaret A.S. Mélange contenant du diméboline et de la mémantine
TR201001117A1 (tr) * 2010-02-15 2011-09-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Dimebolin ve memantin kombinasyonları

Similar Documents

Publication Publication Date Title
Arora et al. Fight fire with fire: Neurobiology of capsaicin-induced analgesia for chronic pain
EP1220689B1 (fr) Medicament pour le traitement du syndrome de fatigue chronique associe avec la fibromalgie et le syndrome de l'intestin irritable.
KR100742001B1 (ko) 평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법
US11690821B2 (en) A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy
HUE033180T2 (en) Peptide compounds for the treatment of difficult to cure epileptic diseases
US20040002546A1 (en) Methods for treating crohn's and other TNF associated diseases
CN108884053B (zh) 预防和/或治疗与衰老有关的认知障碍和神经炎症的方法
US7902251B2 (en) Method for treating pain
JP2002524498A (ja) 機能性及び／又は器質性痛み症候群の治療のための製薬組成物の調製のためのアセチルコリンエステラーゼ阻害剤の使用
UA76753C2 (uk) Комбінація галантаміну або дезоксипеганіну та протизбуджувального агента, її застосування (варіанти) для лікування наркотичної або токсичної залежності
WO2008112238A1 (fr) 2, 8-diméthyl-5- [2- (6-méthylpyridin-3-yl) -éthyl] -2,3,4, 5-tétrahydro- ih- pyrido [4, 3 -b] indole dihydrochlorure (dimebon) pour le traitement de la douleur chronique
US20070129423A1 (en) Method for treating pain
US20070105940A1 (en) Method for treating pain
DeFrates et al. Pharmacologic treatment of neuropathic pain following spinal cord injury
NZ546549A (en) Carbamate compounds for use in preventing or treating anxiety disorders
US20070259945A1 (en) Method for treating pain
CN101636391B (zh) 神经病理性疼痛的预防剂和/或治疗剂
WO2008109521A2 (fr) Procédé de traitement utilisant de l'atranorine
KR100692235B1 (ko) 안지오텐신 ⅱ 길항물질의 신규한 용도
KR20050121236A (ko) 치매 환자에서 초조 증상을 치료하기 위한 카르바마제핀유도체의 용도
AU2002363874A1 (en) Use of desoxypeganine for treating clinical depression
US20110263710A1 (en) Transepithelial methods of using gamma aminobutyric acid compositions for pain relief
Watson et al. Treatment of neuropathic pain: focus on antidepressants, opioids and gabapentin
WO2002043748A1 (fr) Procede de traitement comportant l'administration de la substance p
WO2023215277A1 (fr) Triméprazine destiné à être utilisé dans le traitement de la névralgie du trijumeau et pour réduire la douleur associée à celle-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08742051

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08742051

Country of ref document: EP

Kind code of ref document: A1